Humacyte, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 110.78 million compared to USD 11.97 million a year ago. Basic loss per share from continuing operations was USD 1.07 compared to USD 0.12 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.27 USD | -0.68% | -2.81% | +155.99% |
Jun. 03 | Humacyte Insider Sold Shares Worth $1,561,605, According to a Recent SEC Filing | MT |
May. 30 | Certain Common Stock of Humacyte, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2024. | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+155.99% | 866M | |
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- HUMA Stock
- News Humacyte, Inc.
- Humacyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023